SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,927,640,043 |
| Positions | 120 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $155,867,152 | 287,668 |
| ABIVAX SA | ABVX | SPONSORED ADS | $121,783,649 | 913,880 |
| ENCOMPASS HEALTH CORP | EHC | COM | $103,800,973 | 1,026,919 |
| ENSIGN GROUP INC | ENSG | COM | $96,513,264 | 602,079 |
| VERA THERAPEUTICS INC | VERA | CL A | $94,949,961 | 2,212,770 |
| INVESCO QQQ TR | QQQ | UNIT SER 1 | $72,609,040 | 98,600 |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $66,454,865 | 1,785,941 |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $61,168,871 | 2,798,210 |
| BROOKDALE SR LIVING INC | BKD | COM | $54,649,202 | 3,396,470 |
| IONIS PHARMACEUTICALS INC | IONS | COM | $52,702,794 | 664,684 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.